Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$839M |
| 2 |
Amazon
AMZN
|
+$810M |
| 3 |
Tesla
TSLA
|
+$644M |
| 4 |
TSMC
TSM
|
+$546M |
| 5 |
Johnson & Johnson
JNJ
|
+$389M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$891M |
| 2 |
Home Depot
HD
|
+$441M |
| 3 |
JPMorgan Chase
JPM
|
+$335M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$317M |
| 5 |
ASML
ASML
|
+$315M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.84% |
| 2 | Technology | 15.57% |
| 3 | Consumer Discretionary | 11.88% |
| 4 | Consumer Staples | 10.09% |
| 5 | Financials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
UDMY
3426
DELISTED
Udemy
UDMY
| $198K | ﹤0.01% |
18,800
-6,000
| -24% | -$81K |
|
|
VNTR
3427
DELISTED
Venator Materials PLC
VNTR
| $198K | ﹤0.01% |
366,838
+219,500
| +149% | +$153K |
|
|
NBP
3428
NovaBridge Biosciences American Depositary Shares
NBP
$222M
| $197K | ﹤0.01% |
47,100
-114,000
| -71% | -$432K |
|
3429
MarketWise
MKTW
$53.1M
| $197K | ﹤0.01% |
5,865
+420
| +8% | +$18.3K |
|
|
CAMP
3430
DELISTED
CalAmp Corp.
CAMP
| $197K | ﹤0.01% |
+1,909
| New | +$161K |
|
3431
CervoMed
CRVO
$39.6M
| $196K | ﹤0.01% |
25,873
-3,466
| -12% | -$28.9K |
|
|
SIEN
3432
DELISTED
Sientra, Inc.
SIEN
| $196K | ﹤0.01% |
96,610
+85,350
| +758% | +$295K |
|
|
IHT
3433
InnSuites Hospitality Trust
IHT
$14.9M
| $195K | ﹤0.01% |
117,000
-11,200
| -9% | -$19.6K |
|
3434
Abeona Therapeutics
ABEO
$354M
| $193K | ﹤0.01% |
62,637
-5,500
| -8% | -$20.6K |
|
3435
C4 Therapeutics
CCCC
$503M
| $192K | ﹤0.01% |
32,500
-30,300
| -48% | -$251K |
|
3436
FTAI Infrastructure
FIP
$551M
| $192K | ﹤0.01% |
+65,100
| New | +$180K |
|
3437
Mistras Group
MG
$582M
| $191K | ﹤0.01% |
38,800
-900
| -2% | -$4.08K |
|
|
ELEV
3438
DELISTED
Elevation Oncology
ELEV
| $190K | ﹤0.01% |
199,900
-88,757
| -31% | -$90.1K |
|
3439
Arteris
AIP
$1.36B
| $189K | ﹤0.01% |
43,900
+18,100
| +70% | +$91.2K |
|
|
AMBR
3440
Amber International Holding Ltd
AMBR
$126M
| $189K | ﹤0.01% |
49,203
+10,120
| +26% | +$30.8K |
|
3441
Iris Energy
IREN
$16B
| $188K | ﹤0.01% |
150,400
+127,200
| +548% | +$302K |
|
3442
One Stop Systems
OSS
$327M
| $188K | ﹤0.01% |
62,313
-27,059
| -30% | -$84.4K |
|
|
WDH
3443
Waterdrop
WDH
$359M
| $187K | ﹤0.01% |
56,300
+2,200
| +4% | +$3.78K |
|
3444
Mexco Energy
MXC
$18.6M
| $185K | ﹤0.01% |
14,800
-5,435
| -27% | -$80.5K |
|
|
VINC
3445
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $185K | ﹤0.01% |
9,050
-6,385
| -41% | -$120K |
|
3446
Cytosorbents Corp
CTSO
$22.8M
| $184K | ﹤0.01% |
118,400
-79,396
| -40% | -$118K |
|
|
ONCY
3447
Oncolytics Biotech
ONCY
$95.5M
| $184K | ﹤0.01% |
112,600
+88,000
| +358% | +$134K |
|
3448
Tango Therapeutics
TNGX
$4.32B
| $183K | ﹤0.01% |
25,300
+14,100
| +126% | +$99.2K |
|
|
AEY
3449
DELISTED
ADDvantage Technologies Group
AEY
| $183K | ﹤0.01% |
12,590
+4,970
| +65% | +$88.2K |
|
|
TIO
3450
DELISTED
Tingo Group, Inc. Common Stock
TIO
| $183K | ﹤0.01% |
220,521
+29,100
| +15% | +$24.5K |
|
Similar funds
Jim Simons's Q4 2022 Portfolio in Review
As of Q4 2022, Jim Simons held 4,601 positions worth $73.1B, up 3.4% from $70.7B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons's Q4 2022 filing shows 626 new, 1,390 increased, 2,018 reduced and 524 closed positions. Its largest new stake was Johnson & Johnson: 2,254,125 shares worth $398M. The largest sale was Microsoft, an estimated $891M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2022 buy was Johnson & Johnson: 2,254,125 shares worth $398M.
- Jim Simons added most to Apple in Q4 2022, an estimated $839M increase.
- Jim Simons's biggest Q4 2022 reduction was Novo Nordisk, cutting an estimated $317M.
- Jim Simons fully exited Microsoft in Q4 2022, selling an estimated $891M.
- Jim Simons's ten largest holdings make up 11% of its $73.1B portfolio in Q4 2022.
- Jim Simons opened 626 new positions and closed 524 in Q4 2022.
- Jim Simons's portfolio value rose 3.4% quarter-over-quarter to $73.1B.
Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.